

Accepted Manuscript

Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) versus twice-daily inhaled corticosteroids/long-acting β_2 -agonists (ICS/LABA) in patients with uncontrolled asthma: An open-label, randomized, controlled trial

Philippe Devillier, Marc Humbert, Alain Boye, Wolfgang Zachgo, Loretta Jacques, Carol Nunn, Sarah West, Andy Nicholls, Zeina Antoun, Luminita Spinu, Jean-Marie Grouin

PII: S0954-6111(18)30200-2

DOI: [10.1016/j.rmed.2018.06.009](https://doi.org/10.1016/j.rmed.2018.06.009)

Reference: YRMED 5459

To appear in: *Respiratory Medicine*

Received Date: 25 January 2018

Revised Date: 18 May 2018

Accepted Date: 4 June 2018

Please cite this article as: Devillier P, Humbert M, Boye A, Zachgo W, Jacques L, Nunn C, West S, Nicholls A, Antoun Z, Spinu L, Grouin J-M, Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) versus twice-daily inhaled corticosteroids/long-acting β_2 -agonists (ICS/LABA) in patients with uncontrolled asthma: An open-label, randomized, controlled trial, *Respiratory Medicine* (2018), doi: [10.1016/j.rmed.2018.06.009](https://doi.org/10.1016/j.rmed.2018.06.009).

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) versus twice-daily inhaled corticosteroids/long-acting β_2 -agonists (ICS/LABA) in patients with uncontrolled asthma: an open-label, randomized, controlled trial

Philippe Devillier (CORRESPONDING AUTHOR)

UPRES EA220, Airway Disease Department, Foch Hospital, University Paris-Saclay, Suresnes, France
(P.DEVILLIER@hopital-foch.org)

Marc Humbert

Université Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin Bicêtre; and Service de Pneumologie, Hôpital Bicêtre, Assistance-Publique Hôpitaux de Paris, Le Kremlin Bicêtre, France
(mjc.humbert@gmail.com)

Alain Boye

Nouvelles Cliniques Nantaises, Nantes, France (a.boyé@clinouest.fr)

Wolfgang Zachgo

Lungenzentrum Geesthacht, Geesthacht, Germany (wz@mikloweit-zachgo.de)

Loretta Jacques

GlaxoSmithKline, Respiratory Medicines Development Centre, London, UK
(loretta.a.jacques@gsk.com)

Carol Nunn

GlaxoSmithKline, Respiratory Medicines Development Centre, London, UK (carol.a.nunn@gsk.com)

Sarah West

GlaxoSmithKline, Stockley Park, Uxbridge, UK (sarah.l.west@gsk.com)

Andy Nicholls

GlaxoSmithKline, Stockley Park, Uxbridge, UK (andy.p.nicholls@gsk.com)

Zeina Antoun

GlaxoSmithKline, Rueil-Malmaison, France (zeina.z.antoun@gsk.com)

Luminita Spinu

GlaxoSmithKline, Rueil-Malmaison, France (luminita.x.spinu@gsk.com)

Jean-Marie Grouin

University of Rouen, Rouen, France (grouin2@wanadoo.fr)

Download English Version:

<https://daneshyari.com/en/article/8819843>

Download Persian Version:

<https://daneshyari.com/article/8819843>

[Daneshyari.com](https://daneshyari.com)